Daily Sepsis Research Analysis
Three studies reshape sepsis care across practice and mechanisms: a large meta-analysis shows fluid choice has opposite mortality effects in traumatic brain injury versus other critical illness; a Lancet Microbe cohort reveals common, routinely missed antibiotic heteroresistance in E. coli bacteremia with outcome penalties; and a big-data ICU study links early glycemic variability to 28-day mortality in non-diabetic sepsis. Together they emphasize precision resuscitation, improved microbiology d
Summary
Three studies reshape sepsis care across practice and mechanisms: a large meta-analysis shows fluid choice has opposite mortality effects in traumatic brain injury versus other critical illness; a Lancet Microbe cohort reveals common, routinely missed antibiotic heteroresistance in E. coli bacteremia with outcome penalties; and a big-data ICU study links early glycemic variability to 28-day mortality in non-diabetic sepsis. Together they emphasize precision resuscitation, improved microbiology diagnostics, and tighter glucose variability control.
Research Themes
- Precision fluid resuscitation in critical illness and sepsis
- Antibiotic heteroresistance and diagnostic gaps in bloodstream infections
- Glycemic variability as a prognostic target in sepsis
Selected Articles
1. Effect of Treatment With Balanced Crystalloids Versus Normal Saline on the Mortality of Critically Ill Patients With and Without Traumatic Brain Injury: A Systematic Review and Meta-Analysis.
Across 15 trials (n=35,207), balanced crystalloids reduced mortality versus saline in critically ill patients without TBI (OR 0.93) but increased mortality in those with TBI (OR 1.31), with minimal heterogeneity. In sepsis, balanced fluids showed a non-significant trend to lower mortality (OR 0.92). These data highlight illness-specific effects of fluid composition.
Impact: This PRISMA-compliant meta-analysis reconciles conflicting fluid trials by stratifying on TBI, revealing opposite mortality directions and informing precision resuscitation strategies. It also contextualizes the sepsis subgroup signal.
Clinical Implications: Avoid balanced crystalloids in TBI resuscitation and consider their preferential use in non-TBI critical illness, including sepsis, while awaiting more definitive sepsis-specific trials.
Key Findings
- In non-TBI critical illness, balanced crystalloids lowered mortality vs saline (OR 0.93; 95% CI 0.87–0.98; I2=0%).
- In TBI, balanced crystalloids increased mortality vs saline (OR 1.31; 95% CI 1.03–1.65; I2=0%).
- No consistent differences in secondary outcomes (e.g., renal complications, ICU therapies); data sparse for some TBI outcomes.
- In sepsis patients, balanced crystalloids showed a trend toward lower mortality (OR 0.92; 95% CI 0.83–1.02; I2=0%).
Methodological Strengths
- PRISMA-adherent systematic review and random-effects meta-analysis
- Large cumulative sample (35,207) with low heterogeneity (I2=0%) in key analyses
Limitations
- Some secondary outcomes in TBI lacked sufficient data for pooling
- Trial-level heterogeneity in fluid protocols and co-interventions may persist
Future Directions: Conduct sepsis-specific RCTs comparing balanced crystalloids and saline with predefined subgroups (e.g., hyperchloremia risk, AKI) and mechanistic endpoints; refine TBI-specific fluid guidelines.
BACKGROUND: Some studies suggest that balanced solutions may improve outcomes in critical care patients. However, in patients with traumatic brain injury (TBI) existing data indicate that normal saline may be preferred. We hypothesized that mortality in critically ill patients with and without TBI would differ with the use of balanced salt solutions versus normal saline. METHODS: We conducted a systematic review and meta-analysis to investigate the impact of balanced crystalloids versus normal saline on 90-day mortality in adult critical care patients with and without TBI. Secondary outcomes included length of hospital stay, renal complications, need for vasopressors or mechanical ventilation, and mortality in critically ill patients with sepsis. We followed the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analysis) statement and estimated the odds ratio (OR) and 95% confidence interval (CI) with a random-effects model. RESULTS: We included 15 clinical trials involving 35,207 patients. The OR of mortality with balanced solutions versus saline in patients without TBI was 0.93 (95% CI, 0.87-0.98; P = .01; I 2 = 0%), while the OR for mortality in patients with TBI was 1.31 (95% CI, 1.03-1.65; P = .03; I 2 = 0%). We found no differences in secondary outcomes due to fluid choice although data were unavailable to calculate pooled estimates for some of the secondary outcomes for TBI patients. In patients with sepsis, the OR of mortality with balanced solutions was 0.92 (95% CI, 0.83-1.02; I 2 = 0%). CONCLUSIONS: In comparison to normal saline, balanced solutions were associated with a reduction in mortality in critical care patients without TBI. However, balanced solutions were associated with an increase in mortality in patients with TBI. These findings suggest that the effect of fluid choice on intensive care unit (ICU) outcomes may depend partially on the type of critical illness and in particular in patients with TBI.
2. Prevalence, misclassification, and clinical consequences of the heteroresistant phenotype in Escherichia coli bloodstream infections in patients in Uppsala, Sweden: a retrospective cohort study.
Among 255 E. coli bloodstream infections, heteroresistance was common (gentamicin 43%, piperacillin-tazobactam 9%) and misclassified as susceptible in 96% of cases by routine testing. When patients received the implicated antibiotic, heteroresistance was associated with higher odds of intermediate/ICU admission and mortality. Length of stay was unaffected.
Impact: Demonstrates a prevalent, under-recognized resistance phenotype with direct adverse outcome implications, challenging current susceptibility testing workflows and stewardship practices.
Clinical Implications: Consider heteroresistance in treatment failures; integrate population analysis or alternative detection algorithms for high-risk antibiotics; avoid monotherapy with agents showing BCHR when feasible.
Key Findings
- Breakpoint-crossing heteroresistance was detected in 43% (gentamicin) and 9% (piperacillin-tazobactam) of E. coli isolates; <1% for cefotaxime.
- Routine clinical susceptibility testing misclassified 96% (120/125) of heteroresistant isolates as susceptible.
- In patients treated with the implicated drug, heteroresistance was associated with higher odds of intermediate care (piperacillin-tazobactam BCHR: OR 3.1, 95% CI 1.1–9.6) and ICU admission and mortality (gentamicin BCHR: ICU OR 5.6; mortality OR 7.1).
- Heteroresistance showed no association with length of hospital stay.
Methodological Strengths
- Population analysis profiling to rigorously identify heteroresistance
- Clinically anchored outcomes with 90-day mortality and ICU utilization
Limitations
- Single-region retrospective cohort limits generalizability
- Focused on three antibiotics; broader spectrum agents not assessed
Future Directions: Develop rapid clinical assays for heteroresistance detection and evaluate stewardship interventions and outcome impacts in multicenter prospective studies.
BACKGROUND: Antibiotic heteroresistance is a common bacterial phenotype characterised by the presence of small resistant subpopulations within a susceptible population. During antibiotic exposure, these resistant subpopulations can be enriched and potentially lead to treatment failure. In this study, we examined the prevalence, misclassification, and clinical effect of heteroresistance in Escherichia coli bloodstream infections for the clinically important antibiotics cefotaxime, gentamicin, and piperacillin-tazobactam. METHODS: We conducted a retrospective cohort analysis of patients (n=255) admitted to in-patient care and treated for E coli bloodstream infections within the Uppsala region in Sweden between Jan 1, 2014, and Dec 31, 2015. Patient inclusion criteria were admission to hospital on suspicion of infection, starting systemic antibiotics at the time of admission, positive blood cultures for the growth of E coli upon admission, and residency in the Uppsala health-care region at the time of admission. Exclusion criteria were growth of an additional pathogen than E coli in blood cultures taken at admission or previous inclusion of the patients in the study for another bloodstream infection. Antibiotic susceptibility of preserved blood culture isolates of E coli was assessed for cefotaxime, gentamicin, and piperacillin-tazobactam by disk diffusion and breakpoint crossing heteroresistance (BCHR) was identified using population analysis profiling. The clinical outcome parameters were obtained from patient records. The primary outcome variable was length of hospital stay due to the E coli bloodstream infection, defined as the time between admission and discharge from inpatient care as noted on the physician's notes. Secondary outcomes were time to fever resolution, admission to intermediary care unit or intensive care unit during time in hospital, switching or adding another intravenous antibiotic treatment, re-admission to hospital within 30 days of original admission, recurrent E coli infection within 30 days of admission to hospital, and all-cause mortality within 90 days of admission. FINDINGS: A total of 255 participants with a corresponding E coli isolate (out of 500 screened for eligibility) met the inclusion criteria, with 135 female patients and 120 male patients. One (<1%) of 255 strains was BCHR for cefotaxime, 109 (43%) of 255 strains were BCHR for gentamicin, and 22 (9%) of 255 strains were BCHR for piperacillin-tazobactam. Clinical susceptibility testing misclassified 120 (96%) of 125 heteroresistant bacterial strains as susceptible. The BCHR phenotypes had no correlation to length of hospital stay due to the E coli bloodstream infection. However, patients with piperacillin-tazobactam BCHR strains who received piperacillin-tazobactam had 3·1 times higher odds for admittance to the intermediate care unit (95% CI 1·1-9·6, p=0·041) than the remainder of the cohort, excluding those treated with gentamicin. Similarly, those infected with gentamicin BCHR who received gentamicin showed higher odds for admittance to the intensive care unit (5·6 [1·1-42·0, p=0·043]) and mortality (7·1 [1·2-49·2, p=0·030]) than patients treated with gentamicin who were infected with non-gentamicin BCHR E coli. INTERPRETATION: In a cohort of patients with E coli bloodstream infections, heteroresistance is common and frequently misidentified in routine clinical testing. Several negative effects on patient outcomes are associated with heteroresistant strains. FUNDING: Wallenberg Foundation, Swedish Research Council, and US National Institutes Of Health.
3. Association between various blood glucose variability-related indicators during early ICU admission and 28-day mortality in non-diabetic patients with sepsis.
In 7,049 non-diabetic septic adults, early ICU glucose variability indices showed a J-shaped association with 28-day mortality: risks remained flat below thresholds and rose significantly above them. Each unit increase beyond thresholds in several variability metrics was associated with incremental mortality increases.
Impact: Defines actionable thresholds linking early glucose variability to mortality in non-diabetic sepsis, highlighting variability (not just absolute levels) as a prognostic target.
Clinical Implications: Monitor and minimize early glucose variability in non-diabetic septic patients, potentially via protocolized insulin titration, measurement frequency optimization, and avoidance of iatrogenic swings.
Key Findings
- Large single-center cohort (n=7,049) from MIMIC-IV with ≥3 glucose tests on ICU day 1.
- J-shaped relationships between multiple glucose variability metrics and 28-day mortality; risk flat below thresholds and increased above.
- Per-unit increases beyond thresholds were associated with mortality increases (e.g., +2.82%, +1.13%, +1.96%, +1.37%, +11.19%, +39.04% across specified variability metrics; all with significant 95% CIs).
Methodological Strengths
- Very large sample size with standardized electronic data capture (MIMIC-IV)
- Evaluation of multiple variability metrics and non-linear (J-shaped) risk modeling
Limitations
- Single-center retrospective design limits causal inference and generalizability
- Potential measurement frequency and treatment confounding; thresholds need external validation
Future Directions: Prospective multicenter validation of variability thresholds and interventional trials targeting glucose variability (not only mean glucose) in septic patients.
BACKGROUND: Various blood glucose (BG) variability-related indexes have been widely used to assess glycemic control and predict glycemic risks, but the association between BG variations and prognosis in non-diabetic patients with sepsis remains unclear. METHODS: The single-center retrospective cohort study included 7,049 non-diabetic adults with sepsis who had at least 3 records of bedside capillary point of care BG testing during the first day after ICU admission from MIMIC-IV database (2008 to 2019). Coefficient of variation and standard deviation of glucose (i.e., Glu RESULTS: There is a J-shaped relationship between hospital mortality risk and glucose variability-related indexes in ICU patients with sepsis. The mortality risk remained relatively stable below the threshold of these indexes. However, over the threshold, the 28-day mortality risk increased by 2.82% (95% CI: 1.80-3.85%), 1.13% (95% CI: 0.66-1.60%), 1.96% (95% CI: 0.98-2.95%), 1.37% (95% CI: 0.57-2.16%), 11.19% (95% CI: 6.56-15.98%) and 39.04% (95% CI: 29.86-48.81%) for each unit increases in Glu CONCLUSIONS: High levels of Glu